References
- 1. Monteiro LS, Antunes L, Santos LL, Bento MJ, Warnakulasuriya S. Survival probabilities and trends for lip, oral cavity and oropharynx cancers in Northern Portugal in the period 2000-2009. Ecancermedical-science. 2018;12:855. DOI: 10.3332/ecancer.2018.85510.3332/ecancer.2018.855
- 2. Curado MP, Boyle P. Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol. 2013 May;25(3):229-34. DOI: 10.1097/CCO.0b013e32835ff48c10.1097/CCO.0b013e32835ff48c
- 3. Hoffman HT, Karnell LH, Funk GF, Robinson RA, Menck HR. The National Cancer Data Base Report on Cancer of the Head and Neck. Arch Otolaryngol Head Neck Surg. 1998 Sep 1;124(9):951. DOI: 10.1001/archotol.124.9.95110.1001/archotol.124.9.951
- 4. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. The Lancet. 2008 May;371(9625):1695-709. DOI: 10.1016/S0140-6736(08)60728-X10.1016/S0140-6736(08)60728-X
- 5. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi-eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-53. DOI: 10.1002/ijc.3193710.1002/ijc.3193730350310
- 6. Jimenez L, Jayakar SK, Ow TJ, Segall JE. Mechanisms of Invasion in Head and Neck Cancer. Archives of Pathology & Laboratory Medicine. 2015 Nov 1;139(11):1334-48. DOI: 10.5858/arpa.2014-0498-RA10.5858/arpa.2014-0498-RA746995126046491
- 7. Dhull AK, Atri R, Dhankhar R, Chauhan AK, Kaushal V. Major Risk Factors in Head and Neck Cancer: A Retrospective Analysis of 12-Year Experiences. World J Oncol. 2018;9(3):80-4. DOI: 10.14740/wjon1104w10.14740/wjon1104w603123129988794
- 8. Sturgis EM, Wei Q. Genetic susceptibility-molecular epidemiology of head and neck cancer: Current Opinion in Oncology. 2002 May;14(3):310-7. DOI: 10.1097/00001622-200205000-0001010.1097/00001622-200205000-0001011981277
- 9. Lacko M, Oude Ophuis MB, Peters WHM, Manni JJ. Genetic polymorphisms of smoking-related carcinogen detoxifying enzymes and head and neck cancer susceptibility. Anticancer Res. 2009 Feb;29(2):753-61.
- 10. Freije JMP, Balbín M, Pendás AM, Sánchez LM, Puente XS, López-Otín C. Matrix Metalloproteinases and Tumor Progression. In: Llombart-Bosch A, Felipo V, editors. New Trends in Cancer for the 21stCentury [Internet]. Boston, MA: Springer US; 2003 [cited 2021 Jun 16]. p. 91-107. (Advances in Experimental Medicine and Biology; vol. 532). DOI: 10.1007/978-1-4615-0081-0_910.1007/978-1-4615-0081-0_912908552
- 11. Bellayr IH, Mu X, Li Y. Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments. Future Med Chem. 2009 Sep;1(6):1095-111. DOI: 10.4155/fmc.09.8310.4155/fmc.09.83279413820161478
- 12. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 2007 Jun;29(6):564-72. DOI: 10.1002/hed.2056110.1002/hed.20561
- 13. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug Delivery. 2015 Aug 18;22(6):849-61. DOI: 10.3109/10717544.2014.89834810.3109/10717544.2014.898348
- 14. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncology. 2000 Mar;36(2):207-13. DOI: 10.1016/S1368-8375(99)00088-310.1016/S1368-8375(99)00088-3
- 15. Vilen S-T, Salo T, Sorsa T, Nyberg P. Fluctuating Roles of Matrix Metalloproteinase-9 in Oral Squamous Cell Carcinoma. The Sci World J. 2013;2013:1-11. DOI: 10.1155/2013/92059510.1155/2013/920595
- 16. Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell. 2010 Apr;141(1):52-67. DOI: 10.1016/j. cell.2010.03.015
- 17. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck: Correlation with p53 status, inducible nitric oxide synthase activity, and angiogenesis. Cancer. 2002 Nov 1;95(9):1902-10. DOI: 10.1002/cncr.1091610.1002/cncr.10916
- 18. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem. 1990 Jul 5;265(19):11077-82. DOI: 10.1016/S0021-9258(19)38559-X10.1016/S0021-9258(19)38559-X
- 19. Qin H, Sun Y, Benveniste EN. The Transcription Factors Sp1, Sp3, and AP-2 Are Required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells. Journal of Biological Chemistry. 1999 Oct;274(41):29130-7. DOI: 10.1074/jbc.274.41.2913010.1074/jbc.274.41.2913010506168
- 20. Price SJ, Greaves DR, Watkins H. Identification of Novel, Functional Genetic Variants in the Human Matrix Metalloproteinase-2 Gene. Journal of Biological Chemistry. 2001 Mar;276(10):7549-58. DOI: 10.1074/jbc.M01024220010.1074/jbc.M01024220011114309
- 21. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional Haplotypes in the Promoter of Matrix Metalloproteinase-2 Predict Risk of the Occurrence and Metastasis of Esophageal Cancer. Cancer Res. 2004 Oct 15;64(20):7622-8. DOI: 10.1158/0008-5472.CAN-04-152110.1158/0008-5472.CAN-04-152115492291
- 22. Zhang B, Ye S, Herrmann S-M, Eriksson P, de Maat M, Evans A, et al. Functional Polymorphism in the Regulatory Region of Gelatinase B Gene in Relation to Severity of Coronary Atherosclerosis. Circulation. 1999 Apr 13;99(14):1788-94. DOI: 10.1161/01.CIR.99.14.178810.1161/01.CIR.99.14.178810199873
- 23. Iizuka S, Ishimaru N, Kudo Y. Matrix Metalloproteinases: The Gene Expression Signatures of Head and Neck Cancer Progression. Cancers. 2014 Feb 13;6(1):396-415. DOI: 10.3390/cancers601039610.3390/cancers6010396398059224531055
- 24. O-Charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20.
- 25. Zhang H, Li G, Zhang Z, Wang S, Zhang S. MMP-2 and MMP-9 gene polymorphisms associated with cervical cancer risk. Int J Clin Exp Pathol. 2017 Dec 1;10(12):11760-5.
- 26. Habel AF, Ghali RM, Bouaziz H, Daldoul A, Hadj-Ahmed M, Mokrani A, et al. Common matrix metalloproteinase-2 gene variants and altered susceptibility to breast cancer and associated features in Tunisian women. Tumour Biol. 2019 Apr;41(4):101042831984574. DOI: 10.1177/101042831984574910.1177/101042831984574931014197
- 27. Yari K, Rahimi Z, Moradi MT, Rahimi Z. The MMP-2 -735 C Allele is a Risk Factor for Susceptibility to Breast Cancer. Asian Pacific Journal of Cancer Prevention. 2014 Aug 15;15(15):6199-203. DOI: 10.7314/APJCP.2014.15.15.619910.7314/APJCP.2014.15.15.619925124598
- 28. Beeghly-Fadiel A, Lu W, Long J-R, Shu X, Zheng Y, Cai Q, et al. Matrix Metalloproteinase-2 Polymorphisms and Breast Cancer Susceptibility. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1770-6. DOI: 10.1158/1055-9965.EPI-09-012510.1158/1055-9965.EPI-09-0125274704419454611
- 29. Rollin J, Régina S, Vourc’h P, Iochmann S, Bléchet C, Reverdiau P, et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer. 2007 May;56(2):273-80. DOI: 10.1016/j.lung-can.2006.11.021
- 30. Peng B, Cao L, Ma X, Wang W, Wang D, Yu L. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis. 2010 Jul 1;25(4):371-9. DOI: 10.1093/mutage/geq01510.1093/mutage/geq01520360147
- 31. Shao JY, Cao Y, Miao XP, Huang MY, Deng L, Hao JJ, et al. A single nucleotide polymorphism in the matrix metalloproteinase 2 promoter is closely associated with high risk of nasopharyngeal carcinoma in Cantonese from southern China. Chin J Cancer. 2011 Sep 5;30(9):620-6. DOI: 10.5732/cjc.010.1059210.5732/cjc.010.10592401332421880183
- 32. Sharma KL, Misra S, Kumar A, Mittal B. Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer. Liver Int. 2012 Sep;32(8):1278-86. DOI: 10.1111/j.1478-3231.2012.02822.x10.1111/j.1478-3231.2012.02822.x22621753
- 33. Zhai Y, Qiu W, Dong XJ, Zhang XM, Xie WM, Zhang HX, et al. Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk. Gut. 2007 Mar 1;56(3):445-7. DOI: 10.1136/gut.2006.11270610.1136/gut.2006.112706185678717339256
- 34. Tsai CW, Hsu HM, Wang YC, Chang WS, Shih LC, Sun KT, et al. Contribution of MMP2 Promoter Genotypes to Oral Cancer Susceptibility, Recurrence and Metastasis in Taiwan. Anticancer Res. 2018 Dec;38(12):6821-6. DOI: 10.21873/anticanres.1305510.21873/anticanres.1305530504396
- 35. O-charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metal-loproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncology. 2006 Mar;42(3):257-67. DOI: 10.1016/j.oraloncology.2005.07.00810.1016/j.oraloncology.2005.07.00816275157
- 36. Rosenthal EL, Matrisian LM. Matrix metallopro-teases in head and neck cancer. Head Neck. 2006 Jul;28(7):639-48. DOI: 10.1002/hed.2036510.1002/hed.20365287321716470875
- 37. Chaudhary AK, Pandya S, Mehrotra R, Singh M, Singh M. Role of functional polymorphism of matrix metal-loproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers. 2011 Nov;16(7):577-86. DOI: 10.3109/1354750X.2011.60960210.3109/1354750X.2011.60960221958210
- 38. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Human Genetics. 1999 Nov 15;105(5):418-23. DOI: 10.1007/s00439005112410.1007/s00439005112410598806
- 39. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, et al. A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol(EJSO). 2008 Apr;34(4):450-5. DOI: 10.1016/j.ejso.2007.03.02410.1016/j.ejso.2007.03.02417498910
- 40. Nascimento, GJ Ferreira do et al. Polymorphisms of matrix metalloproteinase-7 and -9 are associated with oral tongue squamous cell carcinoma. Brazilian Oral Res [online]. 2021, v. 35, e019. DOI: 10.1590/1807-3107bor-2021.vol35.001910.1590/1807-3107bor-2021.vol35.001933237244
- 41. Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G, et al. Meta-Analysis of MMP2, MMP3, and MMP9 Promoter Polymorphisms and Head and Neck Cancer Risk. Creighton C, editor. PLoS ONE. 2013 Apr 24;8(4):e62023. DOI: 10.1371/journal.pone.006202310.1371/journal.pone.0062023363472923637955
- 42. Xu T, Zhang S, Qiu D, Li X, Fan Y. Association between matrix metalloproteinase 9 polymorphisms and breast cancer risk: An updated meta-analysis and trial sequential analysis. Gene. 2020 Oct;759:144972. DOI: 10.1016/j.gene.2020.14497210.1016/j.gene.2020.14497232739585